Quarter
Charts

Elanco Animal Health Inc

ELAN

CIK 0001739104 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$1.14B
↑+12.2% +$124Mvs FY2024 (Q4)
Gross Profit
$589M
↑+13.5% +$70Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
37/100
  • Profitability
    0Insufficient data
  • Liquidity
    83Current Ratio 2.17 (above 1.5 = solid)
  • Leverage
    71D/E 0.57 (under 0.5 = conservative)
  • Efficiency
    13Asset Turnover 0.36x (1.0+ = capital-efficient)
  • Growth
    57Revenue YoY +12.2% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project ELAN's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

3%

Trailing 3-yr CAGR was 0.4%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$7.99
Total enterprise IV
$3.96B
Diluted shares
0.50B
Terminal PV
$2.79B (70% of total)
Year-5 FCF
$329M
YearProjected FCFDiscounted PV
+1$293M$266M
+2$301M$249M
+3$310M$233M
+4$320M$218M
+5$329M$204M
Terminal$4.50B$2.79B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$276M
investment in PP&E
Stock-based comp (TTM)
$68M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$13.36B
everything owned
Total liabilities
$6.81B
everything owed
Stockholders' equity
$6.55B
shareholder claim
Net debt
$3.22B
LT debt minus cash

Recent performance · 36 quarters

Revenue↑+12.2% +$124M
$1.14B
Net Income↓-109.3% -$398M
$-34M
Free Cash Flow↓-64.6% -$84M
$46M

Drill down

ELAN Sankey

See Elanco Animal Health Inc's revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

ELAN Charts

36 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

ELAN Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics